What are common DOACs and how are they monitored in the lab?

• A. Dabigatran (direct thrombin inhibitor) commonly prolongs thrombin time; Xa inhibitors (rivaroxaban, apixaban) affect anti-Xa activity; routine PT/aPTT are unreliable.
• B. Dabigatran has no effect on thrombin time; Xa inhibitors prolong PT.
• C. Dabigatran prolongs PT; Xa inhibitors prolong aPTT.
• D. DOACs are monitored by standard PT and aPTT.

Answer: (A)

Direct oral anticoagulants are monitored in the lab in a way that reflects their specific targets. Dabigatran directly inhibits thrombin, so its presence markedly prolongs the thrombin time, making TT a sensitive indicator of its activity. In contrast, Xa inhibitors such as rivaroxaban and apixaban affect the activity of factor Xa, so measuring anti-Xa activity calibrated for the DOAC provides the best estimation of its level. Routine PT and aPTT are not reliable for monitoring DOACs because their sensitivity varies with reagents and they do not consistently reflect drug concentration. Therefore, the combination—dabigatran prolonging thrombin time, Xa inhibitors affecting anti-Xa activity, and PT/aPTT being unreliable for monitoring—is the best description of how these drugs are assessed in the lab.